Ongoing Projects in the Moser Group

Our present projects are investigating biofilms as an independent pharmacological micro-compartment with the aim of better understanding of antibiotic biofilm tolerance.

In biofilm infected chronic wounds our aim is to improve treatments strategies by means of adjunctive S100A8/A9 and hyperbaric oxygen therapy. A similar aim is the case for recurrent or chronic urinary tract infections, where our present focus is investigating the host response significance for the course of the infections and to repurpose avian IgY.

The focus is similar for the live threatening biofilm infections like infective endocarditis, implanted cardiac device and endovascular prosthesis infections. For infective endocarditis we participated in the POET trial, showing it was safe to shift to oral antibiotic treatment and are involved in 2 additional clinical trials (POET II and ASTERIx).

We have developed a vegetation simulation model which is currently being tested for it clinical relevance. We have participated in the ENDOHOT study, testing the feasibility of adjunctive hyperbaric oxygen therapy of infective endocarditis.

Currently, we are investigating how biofilms establish on implantable cardiac heart valve prostheses (TAVI) and endovascular prosthesis (EVAR) with the aim of identifying best possible treatments.